Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chi-Med Sells Shanghai Land Rights for $105 Million

publication date: Dec 9, 2015
Hutchison China MediTech, known as Chi-Med, raised $105 million by selling land-use rights held by a JV subsidiary to the Shanghai government. The subsidiary, Shanghai Hutchison Pharmaceuticals Holding, is a 50-50 joint venture formed two years ago with Sinopharm, one of China's major drug distributors. In return for the cash, SHPL surrendered the remaining 36 years of land-use rights on its factory in the Putuo District of Shanghai. Last year, the JV began construction of a new $100 million factory, with three times the capacity, further from Shanghai's city center. More details....

Stock Symbols: (AIM: HCM) (HK: 1099)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital